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Summary
Introduction: Hepatitis B virus vaccination (HBVV) in the HIV-infected population has
poor reported completion rates and immunological response rates. At our HIV clinic,
we established a vaccine clinic to improve HBVV outcomes using interventions such
as SMS text reminders and double-dose (DD) HBVV for standard-dose non-responders
(SD NRs).
Methods: A ﬁve-year (2003—2008) retrospective review of the completion rates and
immunological response rates for HBVV after the establishment of the dedicated
vaccine clinic was conducted. Statistical signiﬁcance was assumed at p < 0.05, and
the analysis was performed using SPSS (v16).
Results: A total of 354 HIV-infected patients were included. Seventy-ﬁve percent
(268/354) of patients completed the SD HBVV, an 84% (226/268) returned for
the hepatitis B surface antibody evaluation. Only 47.3% (107/226) responded to
standard-dose hepatitis B vaccination. Responders had higher absolute numbers
(p = 0.017) and percentages of CD4 cells (p < 0.001) and were more likely to be receiv-
ing HAART (p = 0.001). There was a 70% (48/69) response rate to DD HBVV among SD
NRs. On-treatment analysis showed an 88% (155/176) overall immunological response
to SD HBVV and DD HBVV, if required.
Conclusion: High HBVV completion and response rates in this HIV cohort were
enabled through the use of multiple interventions, including the use of SMS text
roumessage reminders and
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Introduction
Chronic hepatitis B affects approximately 10% of
HIV-infected people worldwide [1]. HIV/hepatitis B
co-infected people have worse outcomes and are
more likely to develop chronic disease, liver cirrho-
sis and hepatocellular carcinoma [2]. Liver disease
is now considered a leading cause of morbidity and
mortality among HIV-infected individuals [3].
Hepatitis B vaccination remains the mainstay of
disease prevention. The Centers for Disease Con-
trol and Prevention and the British HIV Association
(BHIVA) recommend vaccination for all HIV-infected
individuals who are not immune to hepatitis B
[4,5].
The two main challenges with hepatitis B
vaccination in the HIV-infected population are non-
completion of the full vaccine schedule and a
decreased immunological response [6,7]. BHIVA has
established a target of 95% completion for hep-
atitis B vaccination for HIV-infected attendees of
HIV ambulatory clinics [5]. This target rate is at
odds with clinical practice, with studies showing
completion rates between 17% and 49.6% [6,7].
Because the hepatitis B vaccination series includes
3 injections at 0, 1 and 6 months, a coordi-
nated effort is required by HIV clinics to ensure
that patients are reminded of and encouraged to
attend appointments for vaccination. This contin-
ued effort is challenging for many care providers
for HIV-infected patients. For HIV-infected per-
sons who complete the vaccination series, the
response rate to standard-dose hepatitis B vacci-
nation can be as low as 35% [8]. The administration
of a ‘‘double-dose’’ vaccine to HIV-infected initial
non-responders to hepatitis B vaccination is rec-
ommended to achieve an improved immunological
outcome [5]. For centers that have poor comple-
tion rates for standard-dose hepatitis B vaccination,
double dosing still has the same requirement for
patients to complete a 3-dose series.
To address the challenges regarding the com-
pletion rate and immunological response rate for
hepatitis B vaccination, we established a dedicated
vaccine clinic at our HIV ambulatory care center.
This vaccine clinic was established in 2003 with the
aim of increasing the provision and uptake of all
vaccinations indicated for our HIV-infected cohort.
Regarding hepatitis B vaccination, the vaccine
clinic had two speciﬁc aims: to increase the rate of
completion of the full vaccine series and to increase
the immunological response rate. The interventions
used to increase the rate of completion of the vac-
cine series included the appointment of a full-time
vaccination nurse, patient education and the imple-
mentation of patient reminder systems, including
p
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hort message service (SMS) texts sent to mobile
hones, message card reminders, nurse phone calls
nd ‘‘vaccine passports’’. The intervention used
o increase the immunological response rate was
utomatic enrollment into a double-dose hepatitis
vaccination series for those who did not respond
o standard-dose hepatitis B vaccination.
This study reviews the ﬁrst ﬁve years after the
mplementation of these interventions to assess
heir impact on the completion rate for the hepati-
is B vaccination series and on the immunological
esponse rate in this HIV-infected cohort.
ethods
tudy population
he department of genitourinary medicine and
nfectious diseases at St James’s Hospital, Dublin,
rovides the largest free HIV service in Ireland.
ﬁve-year (January 2003—2008) retrospective
eview of hepatitis B vaccinations administered to
IV-infected patients in this department was con-
ucted.
accine schedule and reminder systems
he hepatitis B vaccinations were administered
n accordance with the recommendations of the
ritish HIV Association and the national guide-
ines [5,9]. The single-dose recombinant (20mcg)
epatitis B vaccination Engerix® was administered
ntramuscularly at 0, 1 and 6 months. The patients
ere given a ‘‘vaccine passport’’ at the ﬁrst visit
hat recorded the vaccine administered and listed
he future dates for the second and third doses and
he hepatitis B surface antibody evaluation. In addi-
ion, SMS text message reminders were sent by the
accine clinic via mobile telephones prior to each
cheduled clinic visit for vaccination. The hepati-
is B vaccinations administered and the hepatitis B
urface antibody results were entered into a clinical
atabase. HIV-infected patients who completed the
accine series but who had hepatitis B surface anti-
ody levels ≤10 IU/L were offered a double-dose
40mcg Engerix®) vaccine series that followed the
ame schedule: 0, 1 and 6 months. These patients
ere also asked to return for a hepatitis B sur-
ace antibody evaluation 6—8 weeks after the third
accine. The patients were considered to have com-
leted the vaccine series if they attended all 3
accination appointments and returned for the hep-
titis B surface antibody evaluation 6 weeks after
he 3rd vaccine.
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First dose HBVV  
354 paents
Second dose HBVV 
331 paents (93.5%)
Third dose HBVV 
268 paents (75.7%)
Completed HBVV and 
HepBsAb 
226 paents (63.8%)
42 did not return for 
HepBsAb within 8 
weeks
63 paents "dropped 
out"
23 paents "dropped 
out"
Key abbreviaons: 
HBVV=hepas B 
virus vaccinaon
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etermination of the hepatitis B vaccination
ompletion and response rates
emographic data, including age, sex, country of
rigin, CD4 count and use of highly active anti-
etroviral therapy (HAART), for each HIV-positive
atient were entered into the database. The CD4
ount (absolute and percentage) used in this study
as the most recent recorded level prior to receiv-
ng the ﬁrst dose of the hepatitis B vaccine. The
eﬁnition of receiving HAART was that the patient
ad been prescribed HAART and the most recent
iral load prior to receiving the ﬁrst hepatitis B
accine dose was less than 100 copies per ml.
Responders (Rs) were deﬁned as individuals hav-
ng hepatitis B surface antibody levels >10 IU/L at
—8 weeks after the 3rd hepatitis B vaccination.
on-responders (NRs) were deﬁned as individuals
aving hepatitis B surface antibody levels ≤10 IU/L
t 6—8 weeks after the 3rd hepatitis B vaccina-
ion. NRs in the HIV group were routinely offered
D hepatitis B vaccination, and the hepatitis B sur-
ace antibody level was evaluated 6—8 weeks after
he 3rd DD hepatitis B vaccination. The hepatitis B
urface antibody titer was used to deﬁne Rs and NRs
fter double dosing.
tatistical analyses
escriptive analysis was performed using percent-
ges for categorical data and means (SD) for
ontinuous data that were normally distributed.
he HIV-positive and HIV-negative groups were
ompared using Pearson’s chi-square statistic for
ategorical data and the independent Student t-
est for the means. Statistical signiﬁcance was
ssumed at p < 0.05, and the analysis was performed
sing SPSS (v16).esults
n total, 268/354 (75%) HIV-positive persons com-
leted the standard-dose vaccine series, and
n
r
b
Table 1 Differences in immunological responders and non
dose.
Responder (n = 107,
Age in years (mean) 38
Sex male 52 (46%)
Absolute CD4 cells/mm3 (mean) 505 (SD 225)
Percentage CD4 cells 27.65 (SD 9.2)
Highly active antiretroviral therapy 65 (56%)igure 1 Hepatitis B virus vaccination standard dose
ompletion rates.
26/268 (84%) returned for hepatitis B surface anti-
ody evaluation within 6 weeks. Fig. 1 shows the
ompletion rates for the standard-dose hepatitis B
accination for the HIV-positive group.
Only 47% (107/226) of those who completed the
accine series had a hepatitis B surface antibody
evel >10 IU/L and were deemed responders. Table 1
hows the differences between the responders and
on-responders to standard-dose hepatitis B vacci-
ation.
In total, 103 of the 107 patients who did not
espond to standard-dose hepatitis B vaccination
egan a double-dose hepatitis B vaccine series, with
-responders to hepatitis B virus vaccination standard
47.3%) Non responder (n = 119, 52.7%) p value
38.8
62 (54%)
430 (SD 218.7) p = 0.017
22.93 (SD 8.6) p < 0.001
51 (44%) p = 0.001
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Table 2 Differences in immunological responders and non-responders to hepatitis B virus vaccination double dose.
Responder (n = 48, 70%) Non responder (n = 21, 30%)
Absolute CD4 cells/mm3 (mean, range) 497 (168—1061) 523 (193—1296)
Percentage CD4 cells 25.4 (10—68) 23 (10—66)
HAART 37 (57%) 9 (44%)
response to SD (107) + response to DD (48)
response to SD (107) + response to DD (48) + no response to DD (21)
=
155
176
Figure 2 Calculation of overall immunological response
76/103 (74%) completing the double-dose vaccine
series. Fig. 3 shows the completion rate for double-
dose hepatitis B vaccination.
In total, 48/69 (70%) patients who completed the
double-dose hepatitis B vaccination series had hep-
atitis B surface antibody levels >10 IU/L and were
deemed responders. Table 2 shows the differences
in the CD4 counts and HAART use between respon-
ders and non-responders to double-dose hepatitis B
vaccination.
The overall immunological response for those
who responded to either standard-dose hepatitis
First  double dose 
HBVV  
103 paents
Second  double 
dose HBVV 
99 paents (96%)
Third double dose 
HBVV 
76 paents (74%)
Completed double 
dose HBVV and 
HepBsAb 
69 paents (67%)
7 did not return 
for HepBsAb 
within 8 weeks
23 paents 
"dropped out"
4 paents 
"dropped out"
Key abbreviaons: 
HBVV=hepas B 
virus vaccinaon
Figure 3 Hepatitis B virus vaccination double dose com-
pletion rates.
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vaccination or double-dose hepatitis B vaccina-
ion was 88% according to on-treatment analysis
155/176). Those who did not respond to standard-
ose hepatitis B vaccination but failed to complete
he double-dose hepatitis B vaccination series were
ot included in the denominator (Fig. 2).
iscussion
o our knowledge, our study is the ﬁrst to eval-
ate the impact of a dedicated vaccine clinic on
he completion rate and immunological response
ate for hepatitis B vaccination in the HIV-positive
opulation.
The hepatitis B vaccination completion rate of
5.5% in this study compares favorably with the
ates found in other studies, which ranged from 50%
o 60% [6,8]. We also had a higher return rate for
he hepatitis B surface antibody evaluation after
he completion of the vaccination series (63.8%)
han observed in other studies, which had return
ates of 25% [6,7]. In the HIV-positive population, it
s recommended that the hepatitis B surface anti-
ody level be evaluated after the completion of
he vaccination series because of the poor immune
esponse to hepatitis B vaccination and the fre-
uent failure to mount a detectable hepatitis B
urface antibody response in this population. In
ur study, only 47.3% of the HIV-positive cohort
esponded to the standard-dose hepatitis B vacci-
ation series. Previous studies found responses to
tandard-dose hepatitis B vaccination ranging from
7% to 55% [10,11]. This lack of response highlights
he importance of evaluating the hepatitis B sur-
ace antibody levels in HIV-positive individuals to
dentify those individuals who have not responded
nd are therefore not immune. After the identi-
cation of non-responders, other strategies, such
s the double dosing strategy that we used in our
accine clinic, can then be used to immunize this
roup.
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The interventions used by our dedicated vac-
ine clinic included the appointment of a full-time
accination nurse, focused patient education and
he use of patient reminder systems, including
eminder record cards, ‘‘vaccine passports’’ and
obile phone SMS text messages to remind patients
f their vaccination appointments. Although SMS
ext message reminders have not previously been
tudied speciﬁcally in HIV-positive cohorts, other
tudies have demonstrated that these reminders
re well accepted by patients, increase vaccine
linic attendance and are cost effective [12,13].
nterventions that were not used by our group
ncluded ﬁnancial incentives and an accelerated
accination schedule. Although ﬁnancial incentives
an motivate drug users to adhere to the vac-
ine schedule, such incentives may have a negative
ffect on other aspects of patient behavior, and we
id not deem it suitable to use this intervention at
ur vaccine clinic [14,15].
HIV-positive patients in this cohort had poor
mmunological responses to standard-dose hepati-
is B vaccination. Only 47.5% of the HIV-positive
atients responded to standard-dose hepatitis B
accination. The factors associated with the lack
f an immune response included lower abso-
ute and percentage CD4 counts and the absence
f HAART. Double-dose hepatitis B revaccination
roved to be effective in 70% of the 69 patients
ho had previously failed to respond to the
tandard-dose vaccine. This ﬁnding highlights the
eneﬁt of double-dose hepatitis B vaccination
n HIV-positive patients to achieve an immune
esponse.
This vaccine clinic had an overall 88% (155/176)
mmune response to hepatitis B vaccination accord-
ng to on-treatment analysis. This rate includes
ll the patients who completed and responded to
tandard-dose hepatitis B vaccination and those
ho did not respond to the standard dose but
ent on to complete the double-dose hepatitis
vaccination series. The on-treatment analysis
xcluded those who did not complete the vaccine
ourse.
Our ﬁndings of a higher hepatitis B vaccina-
ion completion rate and a better overall immune
esponse rate in our patient cohort compared with
ther reported cohorts points to the beneﬁt of a
edicated vaccine clinic.
HIV clinic guidelines regarding hepatitis B vacci-
ation have been shown to be at odds with actual
ractice in some centers [16]. The results of this
tudy demonstrate that the use of multiple vaccine
nterventions can have a positive effect on hepatitis
vaccination completion rates among HIV-positive
atients.mpletion and immunological response 177
imitations
he completion rate in our study may have been
igher than we report herein, as we used strict
nclusion criteria for vaccination and hepatitis B
urface antibody evaluation.
We could not determine which speciﬁc inter-
ention component had the largest impact on
he increased completion rates in our HIV-positive
ohort. All interventions were introduced simulta-
eously as part of the development of a dedicated
accine service.
onclusion
his study demonstrates that the establishment
f a dedicated vaccine service, including the
ppointment of a full-time vaccine nurse, the use
f SMS text messages as reminders, the use of
‘vaccine passports’’ and the use of double-dose
epatitis B vaccination for initial non-responders,
ncreases the completion rate and the immuno-
ogical response rate for hepatitis B vaccination
n HIV-positive patients. The prevention of disease
emains the cornerstone of public health strategies.
his model of vaccine administration serves as a
otential prototype for other health care providers
hat vaccinate large patient cohorts. The author
ow proposes examining the cost effectiveness of
his vaccination program.
unding
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